RhumbLine Advisers’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.01M | Sell |
50,280
-2,222
| -4% | -$44.6K | ﹤0.01% | 2244 |
|
|
2025
Q1 | $1.03M | Buy |
52,502
+2,466
| +5% | +$48.5K | ﹤0.01% | 2156 |
|
|
2024
Q4 | $1.13M | Buy |
50,036
+170
| +0.3% | +$3.83K | ﹤0.01% | 2192 |
|
|
2024
Q3 | $1.27M | Buy |
49,866
+239
| +0.5% | +$6.1K | ﹤0.01% | 2137 |
|
|
2024
Q2 | $1.16M | Buy |
49,627
+11,420
| +30% | +$267K | ﹤0.01% | 2162 |
|
|
2024
Q1 | $672K | Buy |
38,207
+864
| +2% | +$15.2K | ﹤0.01% | 2481 |
|
|
2023
Q4 | $517K | Buy |
37,343
+2,980
| +9% | +$41.2K | ﹤0.01% | 2641 |
|
|
2023
Q3 | $469K | Sell |
34,363
-433
| -1% | -$5.92K | ﹤0.01% | 2648 |
|
|
2023
Q2 | $710K | Buy |
+34,796
| New | +$710K | ﹤0.01% | 2477 |
|